Author’s response to reviews

Title: Congenital emphysematous lung disease associated with a novel Filamin A mutation. Case report and literature review

Authors:
Gloria Pelizzo (gloriapelizzo@gmail.com)
Mirella Collura (mirella.collura@arnascivico.it)
Aurora Puglisi (aurora.puglisi@gmail.com)
Mariapia Pappalardo (mariapia.pappalardo@arnascivico.it)
Emanuela Agolini (emanuele.agolini@opbg.net)
Antonio Novelli (antonio.novelli@opbg.net)
Maria Piccione (maria.piccione@unipa.it)
Caterina Cacace (cacacecaterina@gmail.com)
Rossana Bussani (bussani@units.it)
Giovanni Corsello (giovanni.corsello@unipa.it)
Valeria Calcaterra (v.calcaterra@smatteo.pv.it)

Version: 2 Date: 01 Mar 2019

Author’s response to reviews:

Palermo, March, 1, 2019

Dear Editor,

With pleasure, we resubmit the revised version of our manuscript entitled: “Congenital emphysematous lung disease associated with a novel Filamin A mutation. Case report and literature review.” to be taken into consideration for publication in BMC Pediatrics.

We thank the Editor and Reviewers for their comments. We have addressed these in a point-by-point fashion. All our corrections/modifications are in red and highlighted in yellow.
We wish to thank the reviewers for their constructive comments and we hope that the manuscript is now suitable for publication in its present form.

Thank you for your kind attention and consideration.

Yours Sincerely,
The authors

Editor Comments:
1. While assessing your manuscript we found several instances where the text displayed overlap with other previously published works, in particular:
   Overlap with this previously published work was found mainly in lines 49 – 52 ; 194 – 197 ; and 210 – 213.
   And
   Overlap with this previously published work was found mainly in lines 148 – 150.
   Thank you for your observations. We revised the text

2. In accordance with BMC submission guidelines for Case Reports, please combine the final two sections, Discussion and Conclusions, under one subheading, “Discussion and Conclusions.”
   We combined the sections

3. It was noticed that in your Authors’ contributions subsection:
   The initials GR do not correspond to any author listed in the title page or submission data. Please revise either this subsection or the list of authors to account for this discrepancy. The author Aurora Puglisi was not found to have their initials represented in the subsection. Please revise either this subsection or the list of authors to account for this discrepancy. If two authors have the same initials, please distinguish between them by designating them with numbers 1 and 2. For example: MP1 and MP2. MP1 would correspond to the author furthest up on the author list.
   We revised the author’s contributions subsection

4. Please remove the CARE checklist from the file inventory, as it is no longer needed at this stage of the editorial process.
   We removed the CARE checklist

Reviewer reports:
Ralph Épaud (Reviewer 1): Thanks for considering my commentary and suggestions
Minor concern:
Nadia Nathan (Reviewer 2): The manuscript has been improved a lot. It remains a few fuzzy things and some mistakes in spelling the mutations in Table 1.

- Case presentation
  line 100-102 "After stabilization…” The sentence remains unclear, is a verb missing? We revised the text to clarify (lines 101-104)
  Line 122 "Genomic DNA sequencing… "The term next generation sequencing is missing: "Genomic next generation sequencing…."we revised the text (line 124)
  Line 130 "cystic fibrosis "ar" ?? to be deleted We revised the text (line 132)
  Line 141 "of the patient" is missing at the end of the sentence We revised the text to clarify (line 143)

- Discussion
  Line 180: the ref is missing. We added the ref (line 180)

- Table 1:
The amino-acids are spelled either with 3 letters or 1 letter. Uniformize. Ex: Val / V
  FLNA has to be italized
  *and the number are missing after some fs mutations
  What is "ter"? STOP codon? If so, use *
  As suggested, we revised the table

- Legends to Figure
  Figure 2 legend is repeated twice thank you for your observation, we revised the text (figure legend)
  Figure 3 is still unclear: explain why Tenascin staining is abnormal? We revised the text to clarify (figure legend)
  Figure 4: Use different arrows for PVNH and other abnormalities We revised the figure to clarify (figure 4)